Welcome
Support Centre
24 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Short-term cognitive behavioural therapy and short-term psychoanalytical supportive psychotherapy as treatment for depression: a randomised clinical trial
ISRCTN ISRCTN31263312
DOI 10.1186/ISRCTN31263312
ClinicalTrials.gov identifier
EudraCT number
Public title Short-term cognitive behavioural therapy and short-term psychoanalytical supportive psychotherapy as treatment for depression: a randomised clinical trial
Scientific title
Acronym Praten & Pillen V
Serial number at source N/A
Study hypothesis A randomised clinical trial comparing the efficacy, efficiency and applicability of short-term cognitive behavioural therapy and short-term psychoanalytical supportive psychotherapy in the treatment of depressive disorders.
Lay summary Not provided at time of registration
Ethics approval Approval received from the Dutch council of medical-ethic boards for mental health institutes (Stichting Medisch-Etische Toetsingscommissie Instellingen Geestelijke Gezondheidszorg [METiGG]) on the 12th May 2006 (ref: 5236).
Study design Randomised, parallel group, multicentre trial
Countries of recruitment Netherlands
Disease/condition/study domain Depressive disorders
Participants - inclusion criteria 1. Main diagnosis of:
a. Major Depressive Episode
b. Major Depressive Disorder
c. Depressive Disorder not otherwise specified according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria
2. Hamilton Depression Rating Scale (HDRS) score more than 14
3. Age 18 to 65
4. Written informed consent
Participants - exclusion criteria 1. Bipolar Disorder
2. Depressive disorder with psychotic features
3. Suicide risk
4. Loss of impulse-control
5. Use of non-trial anti-depressants
6. Use of anti-psychotics or mood stabilisers
7. Substance abuse
8. Language problems
9. Contact with same Mentrum location within last six months
Anticipated start date 01/04/2006
Anticipated end date 01/07/2009
Status of trial Completed
Patient information material
Target number of participants 300
Interventions 1. Mild to moderate depression (HDRS score 14 to 24):
Short-term Cognitive Behavioral Therapy or Short-term Psychoanalytical Supportive Psychotherapy, 16 sessions of 45 minutes, during 22 weeks.
2. Severe depressive symptoms (HDRS score more than 24):
Combination treatment: psychotherapy as mentioned above in combination with antidepressants.
Primary outcome measure(s) Depressive complaints according to patient, therapist and independent rater at week 5, 10, 22 and 52.
Secondary outcome measure(s) 1. Quality of life
2. Predictors of treatment outcome at week 22 and 52
Sources of funding Wyeth Pharmaceuticals (The Netherlands) - unrestricted grant
Trial website
Publications 2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/24030613
Contact name Ms  E  Driessen, MSc
  Address Klaprozenweg 111
  City/town Amsterdam
  Zip/Postcode 1033 NN
  Country Netherlands
  Tel +31 (0)20 590 5126
  Email ellen.driessen@mentrum.nl
Sponsor Mentrum Mental Health Care Amsterdam (The Netherlands)
  Address P.O. Box 75848
  City/town Amsterdam
  Zip/Postcode 1070 AV
  Country Netherlands
  Sponsor website: http://www.mentrum.nl/
Date applied 28/12/2006
Last edited 04/11/2013
Date ISRCTN assigned 28/12/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.